GAMMA Investing LLC Takes Position in DexCom, Inc. (NASDAQ:DXCM)

GAMMA Investing LLC acquired a new position in shares of DexCom, Inc. (NASDAQ:DXCM) during the fourth quarter, Holdings Channel.com reports. The institutional investor acquired 2,678 shares of the medical device company’s stock, valued at approximately $325,000.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. Stableford Capital II LLC grew its holdings in DexCom by 2.1% during the fourth quarter. Stableford Capital II LLC now owns 4,367 shares of the medical device company’s stock worth $563,000 after acquiring an additional 88 shares during the period. Valley National Advisers Inc. grew its holdings in DexCom by 73.0% during the fourth quarter. Valley National Advisers Inc. now owns 244 shares of the medical device company’s stock worth $30,000 after acquiring an additional 103 shares during the period. FORVIS Wealth Advisors LLC grew its holdings in DexCom by 0.7% during the fourth quarter. FORVIS Wealth Advisors LLC now owns 16,381 shares of the medical device company’s stock worth $2,033,000 after acquiring an additional 110 shares during the period. Cary Street Partners Investment Advisory LLC grew its holdings in DexCom by 11.1% during the third quarter. Cary Street Partners Investment Advisory LLC now owns 1,153 shares of the medical device company’s stock worth $108,000 after acquiring an additional 115 shares during the period. Finally, HM Payson & Co. grew its holdings in DexCom by 8.5% during the third quarter. HM Payson & Co. now owns 1,480 shares of the medical device company’s stock worth $138,000 after acquiring an additional 116 shares during the period. Institutional investors and hedge funds own 97.75% of the company’s stock.

DexCom Stock Performance

NASDAQ DXCM opened at $137.87 on Thursday. The business’s 50-day moving average price is $130.58 and its 200 day moving average price is $117.88. DexCom, Inc. has a twelve month low of $74.75 and a twelve month high of $142.00. The company has a market capitalization of $54.60 billion, a PE ratio of 105.25, a price-to-earnings-growth ratio of 2.30 and a beta of 1.20. The company has a current ratio of 2.84, a quick ratio of 2.48 and a debt-to-equity ratio of 1.18.

DexCom (NASDAQ:DXCM) last released its earnings results on Thursday, February 8th. The medical device company reported $0.50 earnings per share for the quarter, topping the consensus estimate of $0.43 by $0.07. DexCom had a return on equity of 28.31% and a net margin of 14.95%. The firm had revenue of $1.03 billion for the quarter, compared to the consensus estimate of $1.02 billion. During the same period in the prior year, the business posted $0.34 earnings per share. The firm’s revenue for the quarter was up 26.9% compared to the same quarter last year. On average, research analysts predict that DexCom, Inc. will post 1.76 earnings per share for the current year.

Analysts Set New Price Targets

Several analysts have weighed in on the company. StockNews.com lowered DexCom from a “buy” rating to a “hold” rating in a report on Tuesday. Raymond James upped their target price on DexCom from $147.00 to $151.00 and gave the company a “strong-buy” rating in a report on Tuesday, January 23rd. Royal Bank of Canada assumed coverage on DexCom in a report on Tuesday, March 12th. They issued an “outperform” rating and a $165.00 target price on the stock. Citigroup upped their target price on DexCom from $148.00 to $161.00 and gave the company a “buy” rating in a report on Wednesday, April 3rd. Finally, UBS Group upped their target price on DexCom from $153.00 to $163.00 and gave the company a “buy” rating in a report on Wednesday, April 10th. Three research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, DexCom currently has a consensus rating of “Moderate Buy” and an average price target of $141.40.

Insider Buying and Selling

In other news, EVP Michael Jon Brown sold 2,624 shares of the firm’s stock in a transaction dated Thursday, March 28th. The stock was sold at an average price of $140.04, for a total value of $367,464.96. Following the transaction, the executive vice president now directly owns 68,682 shares in the company, valued at approximately $9,618,227.28. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. In related news, EVP Michael Jon Brown sold 2,624 shares of the business’s stock in a transaction that occurred on Thursday, March 28th. The stock was sold at an average price of $140.04, for a total transaction of $367,464.96. Following the transaction, the executive vice president now directly owns 68,682 shares of the company’s stock, valued at approximately $9,618,227.28. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Kevin R. Sayer sold 81,007 shares of the stock in a transaction that occurred on Tuesday, March 12th. The shares were sold at an average price of $133.36, for a total transaction of $10,803,093.52. Following the completion of the sale, the chief executive officer now directly owns 333,526 shares of the company’s stock, valued at approximately $44,479,027.36. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 189,375 shares of company stock worth $25,530,859. 0.41% of the stock is owned by company insiders.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.